[헬스코리아뉴스 / 서정필] US pharmaceutical company Moderna has decided to develop a vaccine that can prevent influenza (seasonal flu), HIV, and nipaviruses based on mRNA (messenger ribonucleic acid) technology on the 11th (local time), and that it will enter clinical trials within this year. Revealed the plan. It made it clear that it will accelerate the development of a vaccine using mRNA technology following’mRNA-1233′, a corona19 vaccine that hit the jackpot with only $11.7 billion in pre-purchased quantities.
First of all, influenza vaccines (mRNA-1010, mRNA-1020, mRNA-1030) are being developed for type A and B flu, and influenza vaccines are not only influenza, but also fusion of respiratory cells including’severe acute respiratory syndrome’ (SARS). It is making a combination vaccine that can also prevent virus infection (RSV, respiratory syncytial virus) and’human metapneumovirus’ (hMPV).
HIV vaccines (mRNA-1644, mRNA-1574) are also entering phase 1 clinical trials within this year. “HIV infection can lead to acquired immunodeficiency syndrome, killing about 690,000 people each year.” There are about 2 million new cases of HIV infection every year worldwide, so effective vaccine development is an important area.”
Nipa virus vaccine (mRNA-1215) is also being developed. These viruses are usually transmitted from animals, contaminated food, or direct human-to-human transmission.
In addition to Moderna, it is also planning to develop an mRNA-based vaccine against Zika virus and a pandemic influenza or H7N9 vaccine. In addition, various infection prevention vaccines are being developed, including cytoplasmic gallus virus (CMV), Epstein-Barr virus (EBV), human metapneumonia (hMPV), and parainfluenza type 3 (PIV3) vaccine (mRNA-1653).
The mRNA vaccine uses a method of injecting genetic information (mRNA) to generate antibodies against the virus in cells in the human body, unlike previous vaccines that induce immunity by putting dead viruses.
This is the principle that when the cells in the body read the genetic information through the injected vaccine, a virus or part of the virus protein is produced, and an immune system is formed against it. As long as the virus sequence is known, it can be developed in a relatively short time, and since it does not directly put pathogens into the body, it is well evaluated in terms of safety.
Modena CEO Stéphane Bancel shared the plan and said, “The year 2020, which took us to a new challenge, was also an opportunity to prove our capabilities.” “We have shown that an mRNA-based vaccine can prevent COVID-19, and now The development of three new vaccines dealing with influenza, HIV, and Nipa virus is in full swing. In the future (mRNA development) we will expand to 24 programs across all five therapeutic areas.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited